This ongoing, open-label, phase 2/3 trial compared the safety and immunogenicity of the
Omicron BA. 4/BA. 5-containing bivalent mRNA-1273.222 vaccine with the ancestral Wuhan …

Abstract Background Monovalent Omicron XBB. 1.5–containing vaccines were approved for
coronavirus disease 2019 (COVID-19) 2023–2024 immunizations. Methods This ongoing …

We previously presented day 29 interim safety and immunogenicity results from a phase 2/3
study (NCT04927065) comparing the Omicron-BA. 1-containing bivalent vaccine mRNA …

Transmissibility and immune evasion of the recently emerged, highly mutated SARS-CoV-2
BA. 2.87. 1 are unknown. Here, we report that BA. 2.87. 1 efficiently enters human cells but is …

In The Lancet Infectious Diseases, Alberto Mateo-Urdiales and colleagues used a quasi-
experimental study design to evaluate relative vaccine effectiveness (rVE) of a second …

Background Stochastic interventional vaccine efficacy (SVE) analysis is a new approach to
correlate of protection (CoP) analysis of a phase III trial that estimates how vaccine efficacy …

Background Variant-containing mRNA vaccines for COVID-19 to broaden protection against
SARS-CoV-2 variants are recommended based on findings in adults. We report interim …

Background In order to prevent the emergence and spread of future variants of concern of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), developing vaccines …

Introduction Booster vaccinations are required to maintain protection against COVID-19.
COPD patients are at higher risk of developing severe illness following SARS-CoV-2 …

The constant emergence of breakthrough infections with Omicron variants poses an
escalating challenge to the current vaccination strategy. In this study, we investigated the …